TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Simulation gastroscopy test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction rate of >= grade 2 abdominal toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: renal biomarker levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: need for continuous renal replacement therapy at hospital discharge
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Uterine contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Frequency of Hyper- and Hypo-glycemic Events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Half-life (t½)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Curve From Time 0 Through the Last Measurable Concentration (AUC0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Dryness (During Day and Dryness at Night)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Satisfaction of Comfort, Vision, Handling
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vision Quality (During Day and at Night)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the curve from time 0 extrapolated to infinity (AUC0-∞) for serum Pegfilgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Area under the curve from time 0 to the last time point (AUC0-t) for serum Pegfilgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum change from baseline in absolute neutrophil count (ANC); ANC_Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in lesion proportion (%) of full lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference of serum interleukin-6 level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Radiographic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall cost comparison
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Histopathologic examination of ARM +ve LN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ARM LYMPHOEDEMA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incisional hernia rate one year after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the concentration versus time from time zero to infinite time (AUC[0 to infinity])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety as assessed by the number of subjects with adverse events (AE) and serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Clot Time (CT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clot Stiffness (CS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibrinogen Contribution to Clot Stiffness (FCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet Contribution to Clot Stiffness (PCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clot Stability to Lysis (CSL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of epicutaneous pollen allergen administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Worsening of Disc Pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Improvement in Disc Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient's adherence with the diet
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patients with tumor oxygen measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of the experimental regimen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ApoB transport rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety of pVAXrcPSAv53l DNA vaccine
Endpoint domain: Adverse events/effects
Primary endpoint: Pressure (cm H20)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal blood glucose value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of out-of-range INRs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean intakes of Dark Green leafy vegetables, Vitamin A Rich Fruit and Vegetable and Legumes, nuts and seeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women and children consuming Dark Green leafy vegetables, Vitamin A Rich Fruit and Vegetable and Legumes, nuts and seeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of women and children reaching EAR of iron and vitamin A
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Sexual quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative infection outcomes
Endpoint domain: Adverse events/effects
Primary endpoint: Relative mean Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in bulimic symptom frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment Upper Limb (FMA-UL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI-based indices of neural activity during processing of emotional stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: fMRI-based indices of neural activity for subsequently successfully remembered stimuli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Lac/NAA ratio in the basal ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at 48h with a normal aEEG
Endpoint domain: Mortality/survival
Primary endpoint: blood loss in vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Apparent Diffusion Coefficient (ADC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: diagnostic accuracy (sensitivity, specificity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Performance Success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in average Numerical Rating Scale (NRS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: 5-year Progression-Free-Survival
Endpoint domain: Mortality/survival
Primary endpoint: NIRS variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tumor cell dissemination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Safety and tolerability of IT T3011
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose (MTD) of IT T3011
Endpoint domain: Adverse events/effects
Primary endpoint: Outcome as determined by treatment choices
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time to successful placement of catheter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: OSA severity (AHI, mean SpO2, SPo2 nadir)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of patients alive in remission without immunosuppression
Endpoint domain: Mortality/survival
Primary endpoint: Assessment of tourniquet application effectiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pancreatitis reactivation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Rate of survival free of life-threatening valve-related complications
Endpoint domain: Mortality/survival
Primary endpoint: Number of samples collected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Recession Depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Study completion rates - initial collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Study completion rate - second collection
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Diagnostic Yield of Magnetic Resonance Enterography (MRE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Diagnostic Yield of Wireless Capsule Endoscopy (WCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Balance Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Observed Maximum Plasma Concentration (Cmax) of Apremilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measured Time Point (AUC0-t) of Apremilast
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of Apremilast in Terminal Phase (T1/2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of symptomatic Urinary tract infections (UTIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Participant Overall Response Rate (ORR) at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Minimal residual microscopic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of daily physical activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in body fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Abnormal CT finding detection rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time of latency to achieve sensitive block of T10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Duration time of the sensory block of T10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Pharmacokinetics of sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pharmacodynamics of Dipeptidyl peptidase-IV enzyme
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Brief Psychiatry Rating Scale (BPRS) scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Mental load (calm or turbulence of the spirit)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Foot Ankle Pain Disability Survey scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Body Fat Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in segmental duration of vowels of trained words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in segmental duration of vowels of untrained words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in segmental duration of consonants of trained words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in segmental duration of consonants of untrained words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech fluency on trained words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in speech fluency on untrained words
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by visual analogue scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain assessed by pain subscales of KOOS and WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function assessed by function subscales of KOOS and WOMAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of EVENDOL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Units of fresh frozen plasma (FFP) and platelet transfused
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Technical success rate of enbloc ESD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pain level during biopsy collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adoption of recommended levels of physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adoption of recommended levels of fruits and vegetable consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of mental disorders according to the DSM-5
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency and extent of psychological distress (Depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Measurable antibody mediated neutralisation of HPV serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Agreement between Standard of Care Diagnosis and TVDC Image Diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiac and ECG parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinical laboratory safety assessments
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of Liebowitz Social Anxiety Scale (LSAS-SR)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Social Interaction Anxiety Scale (SIAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of Social Phobia Scale (SPS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Subjects With Core Fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Wake After Sleep Onset (WASO)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Central Nervous System (CNS) Progression-free Survival Rate
Endpoint domain: Mortality/survival
Primary endpoint: Macular sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: noninvasive tear breakup time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percent of Glycosylated Hemoglobin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Overall response-rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Perioperative Morphine Equivalents
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lens Centration Acceptance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Primary Gaze Lens Movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory mediators secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Extracellular matrix proteins production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood concentration of pegfilgrastim
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Incidence of ICA-AKI and kidney function damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: In-hospital mortality of cirrhotic patients
Endpoint domain: Mortality/survival
Primary endpoint: Accuracy of the GlucoWatch G2 Biographer and CGMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Inflammatory Cytokine Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Diabetic Retinopathy (DR) pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Diabetic Macular Edema (DME) pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Dry Age-related Macular Degeneration (AMD) pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Hard Drusen in the Mid-periphery pathology
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ophthalmic outcomes
Primary endpoint: Ability to tolerate the device
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to visualize gastrointestinal features
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in Mini-BESTest score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative position of bones in static condition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone dimension
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Response rate of mailed out surveys
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Response rate for saliva kits
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of days with headache per month
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Loss of walk ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability based on adverse experiences
Endpoint domain: Adverse events/effects
Primary endpoint: pupillary diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupillary latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupillary constriction velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pupillary redilation velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HP eradication rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Percentage of subjects achieving ASAS 20
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quantification of MYD88 L265P mutation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in Plasma Vascular Endothelial Growth Factor (VEGF) Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Salivary Oxytocin, Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary Oxytocin, Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Systolic Velocity without trimix
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Disease Free Survival (DFS) of High-risk and Intermediate-risk Relapse Patients
Endpoint domain: Mortality/survival
Primary endpoint: Disease Free Survival (DFS) of Low Risk Relapse Patients
Endpoint domain: Mortality/survival
Primary endpoint: 24h LH pulse frequency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24h LH pulse amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: 24h LH mean concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Number of Participants With Objective Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Reducing heart failure patient rehospitalizations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Has an effect on improving quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Positive effects on blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Incidence of Treatment-emergent adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with successful comprehensive panel testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: frequency of actionable oncogenic mutations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients with long-term safety events
Endpoint domain: Adverse events/effects